Klaus Koefoed

Klaus Koefoed has a strong background in antibody technology and discovery, with significant experience in various roles at Symphogen. Starting in 2022, they are currently serving as the Scientific Director for Antibody Technology Innovation. Prior to this, Klaus worked at Symphogen A/S from 2019 to 2022 as the Director of Antibody Technology. Klaus also held multiple roles at Symphogen from 2005 to 2019, including Director of Antibody Discovery, Team Manager, Interim Team Manager, Principal Scientist, and Senior Scientist, PhD. In these positions, they were responsible for antigen cloning, antibody screening, immunological and kinetic characterization, and the selection of recombinant human therapeutic antibody leads. Klaus also contributed to the development of immunoassays. Before joining Symphogen, Klaus had research experience as a Post Doctoral Fellow at the University of California San Francisco (UCSF) from 2003 to 2005, where they worked in the laboratory of Professor James D. Marks, MD, Ph.D. Klaus also served as a MSc & PhD student at The Scripps Research Institute in La Jolla, CA from 1997 to 2002, focusing on antibody engineering and HIV-1 research under the guidance of Professors Henrik J. Ditzel MD, Ph.D. Klaus began their scientific career as an MSc student at Rigshospitalet, Vævstypelaboratoriet from 1995 to 1997.

Klaus Koefoed received their education in Biochemistry and Immunology from the University of Copenhagen, where they earned both their MSc and PhD. Klaus attended the university from 1991 to 2001, completing their studies within this timeframe.